Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Hospital Germans Trias i Pujol, Barcelona, Spain

Survival: 18.0 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Emcyt
Country: Spain
City/State/Province: Barcelona
Hospital: Hospital Germans Trias i Pujol
Journal: Link
Date: 3/2005

Patients: This Phase II study enrolled 30 men with hormone refractory metastatic prostate cancer. The median age was 69. Metastatic sites included bone, lymph nodes, lung, and liver. Eight patients had received radiotherapy prior to this study.

Treatment: The treatment involved the following chemotherapeutic agents: mitoxantrone and prednisone followed by docetaxel and estramustine. Because of advanced disease, one patient did not complete the docetaxel/estramustine phase.

Toxicities: Grade 1-4 toxicities during the mitoxantrone/prednisone phase included neutropenia. Grade 1-4 toxicities during the docetaxel/estramustine phase included neutropenia, thrombocytopenia, nausea/vomiting, asthenia, edema, and dermatitis. One patient died from infection after beginning docetaxel/estramustine treatment.

Results: The median overall survival for all patients was 18 months. The authors concluded, "Mitoxantrone/prednisone followed by docetaxel/estramustine is a well-tolerated and active regimen in hormone-resistant prostate cancer."

Correspondence: Dr. A. Font

E-mail to a Friend Email Physician More Information